Price
CHART BY
Frequently asked questions
What is Immunic's market capitalization?
The market capitalization of Immunic is $142.21M. Market capitalization is a measure of the total market value of a publicly traded company. It is calculated by multiplying the current stock price by the total number of outstanding shares.
What is the Earnings Per Share (EPS) for Immunic?
Immunic's Earnings Per Share (EPS) over the trailing twelve months (TTM) is -$0.747. EPS indicates the company's profitability on a per-share basis.
What are the analyst ratings and target price for Immunic's stock?
Currently, 9 analysts cover Immunic's stock, with a consensus target price of $5.25. Analyst ratings provide insights into the stock's expected performance.
What is the EBITDA for Immunic?
Immunic's Earnings before interest, taxes, depreciation, and amortization (EBITDA) over the trailing twelve months is -$103.06M. EBITDA measures the company's overall financial performance.
What is the free cash flow of Immunic?
Immunic has a free cash flow of -$85.97M. Free cash flow indicates the cash generated after accounting for cash outflows to support operations and capital assets.
How many employees does Immunic have, and what sector and industry does it belong to?
Immunic employs approximately 92 people. It operates in the Health Care sector, specifically within the Major Pharmaceuticals industry.
What is the free float of Immunic's shares?
The free float of Immunic is 128.76M. Free float refers to the number of shares available for public trading, excluding restricted shares.
Financials
- Market Cap
- $142.21M
- EPS (TTM)
- -$0.747
- Free Float
- 128.76M
- EBITDA (TTM)
- -$103.06M
- Free Cashflow (TTM)
- -$85.97M
Pricing
- 1D span
- $1.03$1.147
- 52W span
- $0.508$1.505
Analyst Ratings
The price target is $5.25 and the stock is covered by 9 analysts.
Buy
9
Hold
0
Sell
0
Information
Immunic, Inc. is a clinical-stage biopharmaceutical company, which develops a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases. It focuses on ulcerative colitis, Crohn’s disease, relapsing-remitting multiple sclerosis, and psoriasis. The firm’s products include IMU-838, IMU-935, and IMU-856. The company was founded in May 2003 and is headquartered in New York, NY.
- Employees
- 92
- Industries
- Major Pharmaceuticals
- Sector
- Health Care
Identifier
- Primary Ticker
- IMUX
Knockouts
Real-time data from LSX · Fundamentals & EOD data from FactSet